X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/ose-flying-solo-after-servier-split-posts-midphase-data-ulcerative-colitis-prospect
https://www.globenewswire.com/news-release/2024/07/24/2917736/0/en/OSE-Immunotherapeutics-Announces-Positive-Efficacy-Results-for-Lusvertikimab-in-the-Phase-2-trial-for-the-treatment-of-Ulcerative-Colitis.html
https://www.pharmaceutical-technology.com/news/boehringer-ose-cancer-immunotherapy/
https://www.globenewswire.com/news-release/2024/07/01/2906374/0/en/OSE-Immunotherapeutics-Announces-Publication-of-Preclinical-Efficacy-Results-with-Lusvertikimab-in-Acute-Lymphoblastic-Leukemia-in-the-Journal-Blood.html
https://www.globenewswire.com/news-release/2024/06/24/2902731/0/en/OSE-Immunotherapeutics-Announces-Commercial-and-Revenue-Sharing-Agreement-in-the-Field-of-CAR-T-cell-Therapies.html
https://www.globenewswire.com/news-release/2024/06/20/2901374/0/en/OSE-Immunotherapeutics-Presents-Preclinical-Data-on-mRNA-Therapeutic-Platform-for-the-Treatment-of-Inflammatory-and-Autoimmune-Disorders-at-the-FOCIS-Annual-Meeting-San-Francisco-J.html
https://www.globenewswire.com/news-release/2024/06/19/2901234/0/en/OSE-Immunotherapeutics-Reports-on-its-2024-General-Shareholders-Meeting-and-the-Evolution-of-the-Board-of-Directors-Ready-to-Drive-the-Strategic-Company-s-Growth.html
https://www.globenewswire.com/news-release/2024/06/05/2893560/0/en/OSE-Immunotherapeutics-and-Nantes-University-Hospital-Present-Positive-Phase-1-2-Study-Evaluating-FR104-VEL-101-Immunotherapy-in-Renal-Transplant.html
https://www.globenewswire.com/news-release/2024/05/30/2890988/0/en/OSE-Immunotherapeutics-Provides-Business-and-Corporate-Update.html
Market Place
Share 
